title: Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.
abstract: Risedronate sodium is a pyridinyl bisphosphonate of proven effectiveness for the treatment and prevention of osteoporosis and Paget's disease of the bone. The aim of this study was to compare the esophageal transit and gastric emptying of the placebo film-coated risedronate tablet when taken with 50 or 120 mL of water in subjects with Kyphosis. A total of 23 patients with radiologically documented osteoporosis participated in a single-center, open-label, crossover gamma scintigraphy study. The mean esophageal transit times were 15.6 s (50 mL) and 12.0 s (120 mL) and the mean gastric emptying half-times were 20.5 min (50 mL) and 14.3 min (120 mL). There was no relationship between the degree of Kyphosis measured from lateral standing radiographs and the esophageal transit time. This study demonstrated that even when taken with a minimal volume of water the esophageal transit and gastric emptying of the film-coated 35 mg weekly risedronate placebo tablet was similar in kyphotic subjects to previously obtained results from healthy control subjects.
authors.affiliation: University Hospital, Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK. alan.perkins@nottingham.ac.uk
authors.forename: Alan C
authors.initials: AC
authors.lastname: Perkins
authors.forename: Malcolm
authors.initials: M
authors.lastname: Frier
authors.forename: P Elaine
authors.initials: PE
authors.lastname: Blackshaw
authors.forename: Robin C
authors.initials: RC
authors.lastname: Spiller
authors.forename: K Julia
authors.initials: KJ
authors.lastname: Fairbairn
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Dansereau
authors.forename: Thomas
authors.initials: T
authors.lastname: Kinghorn
authors.forename: Pat
authors.initials: P
authors.lastname: San
authors.forename: David
authors.initials: D
authors.lastname: Hosking
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004947:Esophagus; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D005746:Gastric Emptying; D005772:Gastrointestinal Transit; D006801:Humans; D007738:Kyphosis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D000068296:Risedronic Acid; D012720:Severity of Illness Index; D013608:Tablets, Enteric-Coated; D016284:Technetium Tc 99m Pentetate; D014867:Water
chemical_list: D050071:Bone Density Conservation Agents; D013608:Tablets, Enteric-Coated; D014867:Water; D000068296:Risedronic Acid; D012968:Etidronic Acid; D016284:Technetium Tc 99m Pentetate